Breaking News, Collaborations & Alliances

ProBioGen, Lava Therapeutics Sign Cell Line Mfg. Pact

To leverage CHO.RiGHT expression platform and DirectedLuck Transposase technology for generation of stable high-titer cell lines

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG and Lava Therapeutics have entered a cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate. Lava Therapeutics works on the development of antibody formats for the successful retrieval and activation of the body’s own immune system to effectively kill cancer cells in the tumor microenvironment. Leveraging its CHO.RiGHT expression platform, including its recently launched DirectedLuck Transposase technology for generation of stable h...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters